Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Health & Healthcare

Australia Begins a Big Push To Sequence Underserved Populations
Australia’s Centre for Population Genomics (CPG), a collaboration between the Garvan Institute of Medical Research and the Murdoch Children’s Research Institute, has launched a new initiative to engage diverse communities in genomic research.

Health & Healthcare

Illumina Launches Strategic Research Collaboration With AstraZeneca To Accelerate Drug Target Discovery
Illumina announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise.

Health & Healthcare

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today
The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensive genomic profiling (CGP). CGP is a next-generation sequencing (NGS) approach that uses a single test to assess hundreds of genes—including relevant cancer biomarkers, as established in medical guidelines and clinical trials—for tumor therapy guidance.

Health & Healthcare

Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications
Illumina, Inc. today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK.

Health & Healthcare

Illumina Genomics Forum To Feature Diverse Lineup of Visionary Global Leaders
Illumina, a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum.

Health & Healthcare

Delivering the Future of Diagnostics and Precision Oncology
At the 34th European Congress of Pathology (ECP) in Basel, Switzerland, September 3 to 7, 2022, pathologists from more than 100 countries will convene to share and gain insights on advancements in their field.

Responsible Business & Employee Engagement

Illumina Deepens Commitment to Customers in China With New Manufacturing Site
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing site in China.

Health & Healthcare

Illumina Genomics Forum To Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics
Illumina, a global leader in DNA sequencing and array-based technologies, announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1.

Health & Healthcare

Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
Illumina, announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.

Innovation & Technology

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
Illumina, a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.
Illumina logo

More from Illumina

  1. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  2. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...

  3. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  4. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  5. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  6. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...